Jaguar Health, Inc. — Form 8-K
Filed August 19, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
In January 2026, Jaguar entered a U.S. commercial licensing agreement with Future Pak (via Woodward Specialty) for exclusive marketing of Mytesi and Canalevia-CA1, recognizing $16M upfront plus $3M early termination fee and a $2M holdback (total ~$21M in Q1 2026). Q2 2026 total revenue fell 59% to $1.2M (vs. $3.0M in Q2 2025); prescription product revenue alone declined 60% to $1.2M. Net loss widened to $12.7M (Q2 2026) from $10.4M (Q2 2025), driven by $3.5M loss on debt extinguishment and $1.9M fair value loss on warrants/notes, though operating loss improved slightly ($7.6M vs. $8.0M) due to $2.5M cut in sales/marketing expenses.
Why this rating
Large upfront revenue ($21M) relative to $3.8M market cap is material, but license shifts recurring Mytesi sales to Future Pak, eliminating future margin. Q2 shows structural revenue decline and worsening net loss despite cost cuts. Clinical progress on crofelemer-MVID (48% parenteral reduction) is promising but pre-revenue. Debt distress signals (extinguishment losses, warrant revaluations) offset licensing upside.
See more from August 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.